Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in PD1-resistant patient-derived explants REHOV ...

New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers     REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally activated ...

Core Insights - Purple Biotech Ltd. has initiated the development of a second tri-specific antibody, IM1305, targeting TROP2, and achieved a manufacturing milestone for its first tri-specific antibody, IM1240, which targets 5T4 [1][4] - The company reported a cash position of $10.5 million as of September 30, 2025, with an expected cash runway into the first half of 2027, supporting the development of its CAPTN-3 technology platform [1][10] Financial Performance - Research and Development Expenses for the three months ended September 30, 2025, were $0.6 million, a decrease of 56.4% from $1.3 million in the same period of 2024, primarily due to reduced costs associated with the CM24 Phase 2 study [5] - General and Administrative Expenses remained consistent at $0.8 million for the three months ended September 30, 2025, compared to the same period in 2024 [6] - The Operating Loss for the three months ended September 30, 2025, was $1.4 million, a decrease of 35.8% from $2.1 million in the same period of 2024 [6] - The Net Loss for the three months ended September 30, 2025, was $1.3 million, or $0.29 per basic and diluted ADS, compared to a net loss of $0.7 million, or $0.39 per basic and diluted ADS, in the same period of 2024 [9] Clinical and Corporate Developments - The company plans to conduct non-GLP and GLP toxicology studies, submit an Investigational New Drug application (IND), and initiate a Phase 1 study for IM1240 in 2026 [2] - IM1240 has demonstrated tumor cell death in patient-derived, treatment-resistant head and neck biopsies, advancing toward first-in-human clinical trials [4] - The CM24 Phase 2 study will utilize identified biomarkers for patient selection in the upcoming Phase 2b study, which is subject to partnering [4] Patent and Intellectual Property - Purple Biotech received an intention to grant a European patent covering NT219 combinations with immunotherapies or MEK inhibitors to overcome tumor resistance [3][5]

Core Insights - Purple Biotech has achieved a commercially viable yield for IM1240, a tri-specific antibody targeting the tumor-associated antigen 5T4, positioning the program competitively for future development [1] - The CAPTN-3 platform has been validated for scalability, indicating its potential for developing complex tri-specific antibodies with competitive yield and purity [2] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [3] - IM1240 is the first tri-specific antibody in development targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [3] Technology and Mechanism - The CAPTN-3 platform generates conditionally activated tri-specific antibodies that engage both T cells and NK cells, inducing a strong localized immune response within the tumor microenvironment [2][3] - The technology incorporates a cleavable capping mechanism that confines therapeutic activity to the tumor microenvironment, potentially increasing the therapeutic window for patients [2][3] Clinical Development - An Investigational New Drug (IND) submission for IM1240 is planned for 2026, with the antibody advancing toward first-in-human clinical trials [1] - NT219 has demonstrated anti-tumor activity in combination with cetuximab in a Phase 1 study and is currently being evaluated in a Phase 2 study for recurrent and/or metastatic squamous cell carcinoma of the head and neck [4]

Core Points - Purple Biotech Ltd. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as the closing bid price for its American Depositary Shares (ADSs) has been below $1.00 for 30 consecutive trading days [1] - The company has a 180-day period until April 14, 2026, to regain compliance by achieving a closing bid price of $1.00 or more for at least ten consecutive business days [2] - The notification does not affect the company's current Nasdaq listing or trading of its ADSs, which will continue under the symbol "PPBT" [3] Compliance and Remediation - If compliance is not regained by April 14, 2026, the company may be eligible for an additional 180 days to cure the deficiency, provided it meets other listing requirements [4] - The company intends to monitor its ADS closing bid price and may consider options to regain compliance, including potentially changing the ADS to ordinary shares ratio [5] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [6] - CAPTN-3 is a preclinical platform utilizing tri-specific antibodies to enhance immune response within the tumor microenvironment, while CM24 is a humanized monoclonal antibody targeting CEACAM1 to block tumor immune evasion [6][7] - NT219 is a novel small molecule that targets IRS1/2 and STAT3, showing anti-tumor activity in combination with cetuximab in clinical studies [7]

Core Viewpoint - Purple Biotech Ltd. is advancing its clinical-stage therapies, particularly NT219, which targets tumor immune evasion and drug resistance, and has received an intention to grant a European Patent for its combination therapies [1][2][3] Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance, with a pipeline that includes NT219, CAPTN-3, and CM24 [4] - The company is headquartered in Rehovot, Israel, and is publicly traded on NASDAQ and TASE under the ticker PPBT [4] Patent and Intellectual Property - The European Patent Office intends to grant a patent for NT219 combinations with leading immunotherapies, which could provide broad protection until 2036 [2] - The patent covers combinations of NT219 with various immunotherapies and chemotherapies, aimed at enhancing treatment sensitivity for resistant tumors [2] Clinical Development - A Phase 2 study for NT219 in combination with immunotherapy is underway, specifically targeting squamous cell carcinoma of the head and neck [3][5] - The study evaluates NT219 with pembrolizumab and cetuximab, building on previous Phase 1 results that showed anti-tumor activity [3][5] - Preclinical data supports the synergistic effects of NT219 with immunotherapy, indicating a shift in the tumor microenvironment from immunosuppressive to immunoreactive [3] Therapeutic Mechanism - NT219 functions as a dual inhibitor targeting IRS1/2 and STAT3, both of which are critical in drug resistance and tumor immune evasion [3][5] - The company is also developing CAPTN-3, a platform of tri-specific antibodies designed to enhance immune response within the tumor microenvironment [4]

Core Viewpoint - Purple Biotech Ltd. has successfully closed a public offering of 5,999,999 American Depositary Shares (ADSs) at a price of $1.00 per share, with additional short-term warrants potentially raising gross proceeds of approximately $12 million if fully exercised [1][3]. Group 1: Offering Details - The public offering included 5,999,999 ADSs, each representing 200 ordinary shares, and short-term warrants to purchase up to 11,999,998 ADSs [1]. - The gross proceeds from the offering were approximately $6 million before deducting fees and expenses [3]. - The short-term warrants have an exercise price of $1.00 per ADS and are exercisable immediately, expiring twenty-four months from issuance [1][3]. Group 2: Use of Proceeds - The net proceeds from the offering will be used for the development of oncology therapeutic candidates and for general working capital and corporate purposes [3]. Group 3: Company Overview - Purple Biotech is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [6]. - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [6]. - CM24 is a humanized monoclonal antibody targeting CEACAM1, and NT219 is a dual inhibitor targeting IRS1/2 and STAT3, with ongoing clinical studies demonstrating anti-tumor activity [6].

Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to overcome tumor immune evasion and drug resistance [6] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with innovative mechanisms targeting various cancer indications [6][7] Public Offering Details - Purple Biotech announced a public offering of 5,999,999 American Depositary Shares (ADSs) at a price of $1.00 per share, with short-term warrants to purchase up to 11,999,998 ADSs [1][3] - The gross proceeds from the offering are expected to be approximately $6 million, with potential additional proceeds of about $12 million from the exercise of short-term warrants [3] Use of Proceeds - The net proceeds from the offering will be utilized for the development of oncology therapeutic candidates and for general working capital and corporate purposes [3] Regulatory Information - The offering is conducted under a registration statement on Form F-1, which was declared effective by the SEC on September 4, 2025 [4]

Core Insights - Purple Biotech Ltd. is advancing its tri-specific antibody IM1240, targeting the tumor-associated antigen 5T4, towards first-in-human clinical trials with an IND submission planned for 2026 [1][6] - The collaboration with Dr. Amir Horowitz focuses on evaluating the CAPTN-3 antibody's effects on patient-derived tumor biopsies, particularly in treatment-resistant cancers [2][3] - IM1240 has shown to induce cancer cell apoptosis in resistant head and neck cancer biopsies, demonstrating a unique synergistic effect not observed in related bispecific antibodies [3][4] Company Overview - Purple Biotech is a clinical-stage company developing therapies to overcome tumor immune evasion and drug resistance, with a pipeline that includes CAPTN-3, CM24, and NT219 [6] - The CAPTN-3 platform utilizes conditionally activated tri-specific antibodies to engage T cells and NK cells, aiming for a strong immune response localized within the tumor microenvironment [6] - IM1240 is the first tri-specific antibody targeting the 5T4 antigen, which is associated with advanced disease and poor clinical outcomes in various solid tumors [6] Research and Development - Dr. Horowitz's research indicates that targeting NKG2A provides a selective checkpoint inhibition strategy, enhancing antitumor activity while minimizing off-target effects [4][5] - Analysis of approximately 26,000 human transcriptomes supports the design of IM1240, showing consistent expression of NKG2A with 5T4 in solid tissues [1][4] - The CAPTN-3 platform's unique design allows for the activation of immune cell subsets with high anti-tumor activity, potentially improving safety and efficacy [4][5]

Core Insights - Purple Biotech is advancing the development of a tri-specific antibody targeting TROP2, which is part of its CAPTN-3 platform aimed at overcoming tumor immune evasion and drug resistance [1][2][8] - The company plans to submit an Investigational New Drug (IND) application for its first CAPTN-3 tri-specific antibody, IM1240, in 2026 [1] - Encouraging preclinical results have shown sustained tumor regression in human triple negative breast cancer (TNBC) models, with significant cell death in various tumor types at low doses [4][5] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [8] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [8][9] - The CAPTN-3 platform utilizes a unique mechanism of action that engages both innate and adaptive immune systems to enhance anti-tumoral responses [8] Technology and Mechanism - The tri-specific antibody IM1305 includes a masked anti-CD3 arm designed to reduce off-target effects while enhancing efficacy in the tumor microenvironment [3][6] - TROP2 is expressed in various solid tumors and is linked to poor prognosis, making it a significant target for therapeutic development [5][6] - The CAPTN-3 platform's ability to recruit multiple immune effectors (T and NK cells) is expected to provide a strong rationale for its effectiveness across diverse tumor types [6][7] Future Prospects - The company is optimistic about the growing interest in TROP2 as a therapeutic target and aims to leverage its technological advancements to accelerate development timelines [7] - Purple Biotech believes that its CAPTN-3 platform can generate multiple programs and expand partnership opportunities in the oncology space [7]